Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVM CEL-SCI	$8.82 +1.4%	$4.76	$1.98 ▼ $39.30	$60.60M	0.52	372,754 shs	200,906 shs
IZTC Invizyne Technologies	$9.70 -2.9%	$10.53	$8.50 ▼ $23.00	$60.64M	N/A	37,647 shs	486 shs
PSTI Pluristem Therapeutics		$1.24	$0.95 ▼ $3.45	$32.35M	1.91	715,259 shs	2,128 shs
ZIVO ZIVO Bioscience	$18.49 +1.3%	$13.73	$7.01 ▼ $22.15	$70.58M	-0.06	1,060 shs	1,222 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVM CEL-SCI	0.00%	+16.94%	+119.70%	+42.30%	-74.34%
IZTC Invizyne Technologies	0.00%	-1.42%	-2.01%	-35.51%	+969,999,900.00%
PSTI Pluristem Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ZIVO ZIVO Bioscience	0.00%	+25.95%	+37.74%	+1.39%	+115.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVM CEL-SCI	1.2606 of 5 stars	0.0	4.0	0.0	0.0	2.5	1.7	0.6
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	0.2462 of 5 stars	0.0	3.0	0.0	0.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVM CEL-SCI	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A
PSTI Pluristem Therapeutics	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	$20K	0.00	N/A	N/A	$1.80 per share	0.00
ZIVO ZIVO Bioscience	$15.85K	4,452.77	N/A	N/A	($0.81) per share	-22.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVM CEL-SCI	-$26.92M	-$9.77	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
IZTC Invizyne Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	-$49.87M	-$1.47	N/A	N/A	N/A	N/A	-100.63%	-55.46%	N/A
ZIVO ZIVO Bioscience	-$7.78M	-$2.58	N/A	∞	N/A	N/A	N/A	-2,240.92%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVM CEL-SCI	0.66	1.07	1.09
IZTC Invizyne Technologies	N/A	N/A	N/A
PSTI Pluristem Therapeutics	0.57	8.22	8.22
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVM CEL-SCI	12.08%
IZTC Invizyne Technologies	N/A
PSTI Pluristem Therapeutics	16.94%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
CVM CEL-SCI	9.93%
IZTC Invizyne Technologies	N/A
PSTI Pluristem Therapeutics	5.40%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVM CEL-SCI	43	6.88 million	64.67 million	Optionable
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A
PSTI Pluristem Therapeutics	153	32.35 million	30.60 million	Optionable
ZIVO ZIVO Bioscience	10	3.82 million	2.91 million	Not Optionable

PSTI, ZIVO, IZTC, and CVM Headlines

Recent News About These Companies

Analyzing ZIVO Bioscience (NASDAQ:ZIVO) & Protalix BioTherapeutics (NYSE:PLX)

August 15 at 3:39 AM | americanbankingnews.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTI, ZIVO, IZTC, and CVM Company Descriptions

CEL-SCI NYSE:CVM

$8.82 +0.12 (+1.38%)

As of 02:57 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Invizyne Technologies NASDAQ:IZTC

$9.70 -0.29 (-2.90%)

As of 08/15/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Pluristem Therapeutics NASDAQ:PSTI

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

ZIVO Bioscience NASDAQ:ZIVO

$18.49 +0.24 (+1.32%)

As of 11:58 AM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time